Comparative 2-D Tumor Analysis in Familial Gliomas

This study is currently recruiting participants.
Verified May 2012 by AHS Cancer Control Alberta
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00125710
First received: July 29, 2005
Last updated: May 14, 2012
Last verified: May 2012
  Purpose

The treatment for patients with malignant brain tumors is disappointing. The disease is incurable and virtually all patients die from their disease. Despite the devastating nature of this illness which affects all age groups, its cause remains unexplained. Family identification with careful clinical and molecular study have led to the discovery of the genes that cause a number of other devastating diseases like retinoblastoma, cystic fibrosis, and Huntington's chorea. The investigators propose to study the genetic changes in patients with familial glioma as a first step in identifying the gene(s) that cause these tumors.


Condition
Malignant Glioma

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Comparative 2-D Tumor Analysis in Familial Gliomas

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Estimated Enrollment: 5
Study Start Date: June 1998
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Detailed Description:

The investigators propose to study the genetic changes in patients with familial glioma as the first step in identifying the gene(s) that cause these tumors. With informed consent, DNAs from tumor and non-tumor tissue, histologic sections, pedigrees and detailed clinical information will be acquired for patients with familial gliomas. A genomic screening methodology named 2D genomic scanning will be used. Differences detected between the tumor and normal tissues (blood, fibroblasts) will identify events occurring in the tumoral process. A comparison of the events in familial and sporadic gliomas will outline some of the pathways suspected to be involved both in tumor initiation and progression. Briefly, DNA fragments are amplified with the polymerase-chain-reaction (PCR) from tumor and normal tissue using primers designed to identify 100 to 1000 random sites within the genome. The PCR primers will hybridize throughout the genome and generate a manageable number of short PCR products that are detected by gel electrophoresis and autoradiography. The PCR for both tumor and constitutional tissues are amplified through 20 to 25 cycles to ensure adequate signal but to avoid entering a non-exponential phase of the PCR amplification. The products are radiolabelled and then run on a standard sequencing gel. The single lane containing labelled PCR products is cut out and then overlaid onto a denaturing grading gel with a 10 to 75% grading of denaturant. The labelled DNA is then separated in the second dimension and the DNA is detected by Southern Transfer to nylon membrane or by gel-drying and direct exposure film. A direct comparison of PCR signals from the tumor and constitutional tissue identifies the loss or gain of signal which reflects the same phenomena within the genome. The isolation and characterization of fragment consistently altered in gliomas will provide the first step in the search for genes responsible in the initiation and progression of gliomas. Because of the collaboration among investigators of different centres in Canada, the current investigators have a unique opportunity to perform the study on the largest collection of familial gliomas in the world. They expect several genomic abnormalities in each tumor. Some of these may be seen in several patients. Data will be analyzed primarily using descriptive statistics, with frequency of genetic abnormalities at different chromosomal locations described.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • Malignant glioma with a blood relative with history of malignant glioma

Exclusion Criteria:

  • Inability to give consent
  • Above criteria not met
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00125710

Contacts
Contact: Wilson Roa, MD 780-432-8783 wilsonro@cancerboard.ab.ca

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact    780-432-8783    clinical_trials_cci@cancerboard.ab.ca   
Principal Investigator: Wilson Roa, MD         
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Wilson Roa, MD AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00125710     History of Changes
Other Study ID Numbers: CNS-659
Study First Received: July 29, 2005
Last Updated: May 14, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
cryogenic analysis
oncogenes

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on April 17, 2014